ABOS vs INCY · $73.3M cap vs P/E 14, rev $5.14B
Acumen Pharmaceuticals Inc (ABOS) versus Incyte Corporation (INCY) — a side-by-side from cached financials, not a winner call.
Acumen Pharmaceuticals Inc (ABOS) is a biotechnology company listed on US.
Incyte Corporation (INCY) is a biotechnology company listed on US.
ABOS does not have a complete income-statement cache yet.
Latest reported INCY revenue for 2025-12-31 was $5.14B. Net income was $1.29B. Revenue was up 21.2% from 2024-12-31 to 2025-12-31. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
ABOS currently screens at market cap $73.3M. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
Not investment advice. Open the ABOS and INCY stock pages for the full models.
Not investment advice.